

an international reproductive health journal

Contraception

Volume 98, Number 1, July 2018

Publication information: *Contraception* (ISSN 0010-7824) is published monthly by Elsevier Inc., 230 Park Avenue, New York, NY 10169. Periodicals postage paid at New York, NY, and additional mailing offices.
USA POSTMASTER: Send address changes to *Contraception*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

Annual subscription rates: United States and possessions: individual, \$503; institution, \$1,782. All other countries: individual, \$585; institution, \$1,875.

Orders, claims, and journal inquiries: Please visit our Support Hub page <https://service.elsevier.com> for assistance.

Advertising information: Advertising orders and inquiries can be sent to: USA, Canada and South America: Le-Andrea Sylvester, Elsevier Inc., 230 Park Avenue, New York, NY 10169. Tel.: (212) 633-3649, e-mail: le.sylvester@elsevier.com.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169; E-mail: reprints@elsevier.com.

Author information: For full and complete Author Information, please go to: <http://www.contraceptionjournal.org/authorinfo>.

Author inquiries: You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://service.elsevier.com>.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

© 2018 by Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Inc., and the following terms and conditions apply to their use:


Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK)/(+1) 215 239 3804 (USA).

Derivative Works: Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage: Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Notice: No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

 This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

Commentary

- 1 Heavy Menstrual Bleeding: is Tranexamic Acid A Safe Adjunct to Combined Hormonal Contraception?
JG Thorne, PD James, RL Reid

- 4 Ensuring Our Research Reflects Our Values: The Role of Family Planning Research in Advancing Reproductive Autonomy
Christine Dehlendorf, Reiley Reed, Edith Fox, Dominika Seidman, Cara Hall, Jody Steinauer

Review Articles

- 8 A Systematic Review of Contraceptive Continuation Among Women Living With HIV
Catherine S. Todd, Tracy C. Anderman, Sarah Long, Landon Myer, Linda-Gail Bekker, Gregory A. Petro, Heidi E. Jones
- 25 Factors Associated With Low-lying Intrauterine Devices: A Cross-sectional Ultrasound Study in A Cohort of African-American Women
Malana Moshesh, Tina Saldana, Elizabeth Deans, Tracy Cooper, Donna Baird
- 30 Low-sensitivity Urine Pregnancy Testing to Assess Medical Abortion Outcome: A Systematic Review
Elizabeth G. Raymond, Tara Shochet, Hillary Bracken

Original Research Articles

- 36 Developing Strategies to Address Contraceptive Needs of Adolescents: exploring Patterns of Use Among Sexually Active Adolescents in 46 Low- and Middle-income Countries
Amanda M. Kalamar, Özge Tunçalp, Michelle J. Hindin
- 41 "It Is My Business": A Mixed-Methods Analysis of Covert Contraceptive Use Among Women in Rakai, Uganda
Craig J Heck, Stephanie A Grilo, Xiaoyu Song, Tom Lutalo, Neema Nakyanjo, John S Santelli
- 47 The Sexual and Reproductive Health of Foreign-born Women in the United States
Athena Tapales, Ayana Douglas-Hall, Hannah Whitehead
- 52 Unintended Pregnancy and Interpregnancy Interval By Maternal Age, National Survey of Family Growth
Katherine A. Ahrens, Marie E. Thoma, Casey E. Copen, Brittni N. Frederiksen, Emily J. Decker, Susan Moskosky

(Contents continued)

- 56** Maintaining Physiologic Testosterone Levels During Combined Oral Contraceptives By Adding Dehydroepiandrosterone: II. Effects on Sexual Function. A Phase II Randomized, Double-blind, Placebo-controlled Study
Rik H.W. van Lunsen, Yvette Zimmerman, Herjan J.T. Coelingh Bennink, Hanneke M.M. Termeer, Nicole Appels, Bart C.J.M. Fauser, Ellen Laan
- 63** Changes in Uptake and Cost of Long-acting Reversible Contraceptive Devices Following the Introduction of A New Low-cost Levonorgestrel IUD in Utah's Title X Clinics: A Retrospective Review
Lauryn P. Roth, Jessica N. Sanders, Rebecca G. Simmons, Holly Bullock, Elizabeth Jacobson, David K. Turok
- 69** The Prevalence and Impacts of Crisis Pregnancy Center Visits Among A Population of Pregnant Women
Katrina Kimport, Rebecca Kriz, Sarah C.M. Roberts
- Case Report**
- 74** Use of Copper Intrauterine Device in Transgender Male Adolescents
Sari Bentsianov, Lonna Gordon, Ariella Goldman, Adam Jacobs, John Steever